Please login to the form below

Not currently logged in
Email:
Password:

Xalkori

This page shows the latest Xalkori news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

There were 17 patients in the Lorbrena arm and 13 in the Xalkori arm with measurable brain metastases based on baseline imaging. ... In addition, the intracranial duration of response was 12 months or longer in 79% of Lorbrena-treated patients compared

Latest news

More from news
Approximately 25 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    In addition Merck KGaA also gets the right to co-promote Xalkori in the US and other "key" markets.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    of Xalkori, below - the drug can achieve accelerated approval on the basis of an interim analysis or phase II data before OS is established. ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown but positive data in morbidity (symptom improvement

  • Who tops the pharma list? Who tops the pharma list?

    Pfizer's Xalkori is just one example of this.”. Alongside oncology, treatments for immunology and metabolic diseases rank among the fastest-growing therapeutic classifications.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...